Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease

Gastroenterology. 2017 Feb;152(2):451-462.e2. doi: 10.1053/j.gastro.2016.10.013. Epub 2016 Oct 18.


The management of the pregnant patient with inflammatory bowel disease is complicated by multiple providers, misinformation, and a disease entity that, particularly when active, can adversely affect pregnancy outcomes. This article seeks to frame the debate on medication safety in pregnancy and lactation using the US Food and Drug Administration's new Pregnancy and Lactation Labeling Rule and the most up-to-date safety information to discuss the risks and benefits of using each class of inflammatory bowel disease medication.

Keywords: Anti−Tumor Necrosis Factor; Inflammatory Bowel Disease; Pregnancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminosalicylic Acids / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Biological Products / therapeutic use*
  • Breast Feeding
  • Congenital Abnormalities / epidemiology*
  • Drug Labeling
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Inflammatory Bowel Diseases / drug therapy*
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Pregnancy Outcome / epidemiology
  • Risk
  • United States
  • United States Food and Drug Administration


  • Aminosalicylic Acids
  • Anti-Bacterial Agents
  • Biological Products
  • Glucocorticoids
  • Immunologic Factors